as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti
Company profile
Ticker
RVTY
Exchange
Website
CEO
Prahlad Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EG&G INC, PERKINELMER INC
SEC CIK
Corporate docs
Subsidiaries
2Cure, LLC • BioLegend CNS, Inc. • BioLegend, Inc. • BioLegend Ventures, LLC • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Oxford Immunotec USA, Inc. • Qognit, Inc. ...
IRS number
42052042
RVTY stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Results of Operations and Financial Condition
1 Feb 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Results of Operations and Financial Condition
9 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Results of Operations and Financial Condition
30 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
RVTY
Earnings call transcript
2023 Q4
1 Feb 24
RVTY
Earnings call transcript
2023 Q3
30 Oct 23
RVTY
Earnings call transcript
2023 Q2
1 Aug 23
RVTY
Earnings call transcript
2023 Q1
11 May 23
RVTY
Earnings call transcript
2023 Q1
11 May 23
RVTY
Earnings call transcript
2022 Q4
14 Feb 23
RVTY
Earnings call transcript
2022 Q3
8 Nov 22
RVTY
Earnings call transcript
2022 Q3
8 Nov 22
RVTY
Earnings call transcript
2022 Q2
5 Aug 22
RVTY
Earnings call transcript
2022 Q2
1 Aug 22
Latest ownership filings
4
Anita Gonzales
16 Apr 24
4
Prahlad R. Singh
27 Mar 24
4
Anita Gonzales
21 Mar 24
4
ALEXIS P MICHAS
1 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
4
Tajinder S Vohra
29 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
Joel S Goldberg
26 Feb 24
4
Prahlad R. Singh
26 Feb 24
144
Notice of proposed sale of securities
23 Feb 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn |
Cash burn (monthly) | 65.12 mm | (no burn) | (no burn) | (no burn) | 11.16 mm | (no burn) |
Cash used (since last report) | 440.67 mm | n/a | n/a | n/a | 75.53 mm | n/a |
Cash remaining | 697.29 mm | n/a | n/a | n/a | 1.06 bn | n/a |
Runway (months of cash) | 10.7 | n/a | n/a | n/a | 95.2 | n/a |
Institutional ownership, Q4 2023
44.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 379 |
Opened positions | 46 |
Closed positions | 159 |
Increased positions | 128 |
Reduced positions | 146 |
13F shares | Current |
---|---|
Total value | 5.80 tn |
Total shares | 54.70 mm |
Total puts | 3.80 k |
Total calls | 20.50 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.18 mm | $1.55 tn |
Capital Research Global Investors | 7.67 mm | $838.08 bn |
STT State Street | 5.18 mm | $566.74 bn |
MS Morgan Stanley | 2.33 mm | $254.27 bn |
Independent Franchise Partners | 1.93 mm | $210.52 bn |
Mitsubishi UFJ Kokusai Asset Management | 1.79 mm | $188.37 bn |
IVZ Invesco | 1.52 mm | $165.87 bn |
Pictet Asset Management Holding | 1.28 mm | $139.80 bn |
NTRS Northern Trust | 1.17 mm | $127.40 bn |
Dimensional Fund Advisors | 1.02 mm | $112.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Anita Gonzales | Common Stock | Payment of exercise | Dispose F | No | No | 103.49 | 108 | 11.18 k | 4,198 |
26 Mar 24 | Singh Prahlad R. | Common Stock | Gift | Acquire G | Yes | No | 0 | 12,075 | 0.00 | 37,163 |
26 Mar 24 | Singh Prahlad R. | Common Stock | Gift | Dispose G | No | No | 0 | 12,075 | 0.00 | 90,195 |
1 Mar 24 | Anita Gonzales | Common Stock | Grant | Acquire A | No | No | 0 | 715 | 0.00 | 4,306 |
1 Mar 24 | Anita Gonzales | NQ Stock Option Common Stock | Grant | Acquire A | No | No | 107.48 | 1,978 | 212.60 k | 1,978 |
29 Feb 24 | Michas Alexis P | Common Stock | Sell | Dispose S | No | No | 109.98 | 5,000 | 549.90 k | 55,604 |
27 Feb 24 | Vohra Tajinder S | Common Stock | Sell | Dispose S | No | Yes | 105.66 | 5,266 | 556.41 k | 26,113 |
27 Feb 24 | Vohra Tajinder S | Common Stock | Sell | Dispose S | No | Yes | 104.84 | 2,652 | 278.04 k | 31,379 |
27 Feb 24 | Vohra Tajinder S | Common Stock | Option exercise | Acquire M | No | No | 54.565 | 7,918 | 432.05 k | 34,031 |
27 Feb 24 | Vohra Tajinder S | NQ Stock Option Common Stock | Option exercise | Acquire M | No | No | 54.565 | 7,918 | 432.05 k | 0 |
News
Revvity Signals Software Unveils Signals Clinical Solution To Accelerate Critical Clinical Trial Insights And Data-Driven Decisions
12 Feb 24
Stifel Maintains Hold on Revvity, Raises Price Target to $110
2 Feb 24
Keybanc Maintains Overweight on Revvity, Raises Price Target to $126
2 Feb 24
Raymond James Maintains Outperform on Revvity, Raises Price Target to $127
2 Feb 24
Revvity Q4 Adjusted EPS $1.25 Beats $1.16 Estimate, Sales $695.90M Beat $677.94M Estimate
1 Feb 24
Press releases
Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
15 Apr 24
Preliminary Injunction Granted to Enforce Revvity's Rights and Cloud Software Group's Obligations Related to Spotfire Software
2 Apr 24
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
20 Mar 24
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
18 Mar 24
Revvity to Present at Upcoming Investor Conferences
21 Feb 24